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Introduction {#bjs550154-sec-0005}
============

The conceptual aim of parenchymal‐sparing or non‐anatomical resection (NAR) for colorectal liver metastases (CRLM) is to preserve as much functional parenchyma as possible in order to decrease the risk of postoperative liver failure and facilitate future repeat resection in the event of intrahepatic recurrence[1](#bjs550154-bib-0001){ref-type="ref"}, [2](#bjs550154-bib-0002){ref-type="ref"}, [3](#bjs550154-bib-0003){ref-type="ref"}. Quantifying the effect of the surgical approach on morbidity and mortality, as well as disease‐free survival (DFS) and overall survival (OS) has been difficult. Data from studies published to date have been conflicting, with some favouring NAR[2](#bjs550154-bib-0002){ref-type="ref"}, [4](#bjs550154-bib-0004){ref-type="ref"}, [5](#bjs550154-bib-0005){ref-type="ref"} whereas others support anatomical resection (AR)[6](#bjs550154-bib-0006){ref-type="ref"}, [7](#bjs550154-bib-0007){ref-type="ref"}.

A central issue in the debate is the possible confounder that large tumours may inherently be more prone to compromising vital inflow or outflow structures than small tumours, thereby necessitating AR. Differences in tumour size between groups may also reflect different tumour biology. Numerous previous studies[8](#bjs550154-bib-0008){ref-type="ref"}, [9](#bjs550154-bib-0009){ref-type="ref"}, [10](#bjs550154-bib-0010){ref-type="ref"}, [11](#bjs550154-bib-0011){ref-type="ref"} comparing AR and NAR did not account for tumour size and number, or failed adequately to control for the potential effect of these variables in multivariable analysis. Several groups have attempted to circumnavigate this by either limiting the analysis to small solitary (less than 30 mm)[2](#bjs550154-bib-0002){ref-type="ref"} or multiple[12](#bjs550154-bib-0012){ref-type="ref"} tumours, or performing case‐controlled analyses[5](#bjs550154-bib-0005){ref-type="ref"}, [13](#bjs550154-bib-0013){ref-type="ref"}. This may, however, result in selection bias for good prognostic lesions, and so conclusions may not be applicable to the full spectrum of disease. Other studies have failed to define AR or had substantial missing data. Consequently, there is ongoing controversy about whether NAR for CRLM leaves undetected residual disease, compromises resection margins, or increases the rate of intrahepatic recurrence[14](#bjs550154-bib-0014){ref-type="ref"}, [15](#bjs550154-bib-0015){ref-type="ref"}.

The hypothesis of the present study was that resection type (anatomical or non‐anatomical) does not influence oncological outcomes after liver resection for CRLM as long as an R0 resection margin is achieved. The aim of this study was to investigate the impact of resection type on short‐ and long‐term outcomes by controlling for tumour size and number after applying a propensity score (PS) analysis to the final model using inverse probability of treatment weighting (IPTW).

Methods {#bjs550154-sec-0006}
=======

This was a retrospective study with data from a prospectively developed database. Included were consecutive patients with CRLM who underwent liver resection with curative intent from January 1999 to December 2016 at the Northern Upper Gastrointestinal Surgery Unit, Royal North Shore and North Shore Private Hospitals, Sydney, New South Wales, Australia. This expands on previous work[16](#bjs550154-bib-0016){ref-type="ref"} published by the authors\' group, by including a larger number of patients as well as the corresponding primary tumour variables. Patients were excluded if they had simultaneous AR and NAR, or an R2 resection. Those who underwent repeat liver resections were included in the analyses but were censored on the date of detection of their recurrence. Ethical approval for the study was provided by the Human Research Ethics Committee of the Northern Sydney Local Health District and the North Shore Private Hospital Ethics Committee.

Resection technique and perioperative factors {#bjs550154-sec-0007}
---------------------------------------------

Liver resection nomenclature was documented as per the Brisbane 2000 terminology[17](#bjs550154-bib-0017){ref-type="ref"}. NAR was defined as resection of a lesion without regard to hepatic segmental anatomy. AR was defined by specific procedure types including: extended right or left hepatectomy, right or left hepatectomy, central liver resection, right posterior sectionectomy, right anterior sectionectomy, left lateral sectionectomy or caudate resection. ARs were further assigned an externally validated complexity score[18](#bjs550154-bib-0018){ref-type="ref"}. Primary colorectal cancer factors included Dukes\' class and complications (if any) after the primary colorectal resection. Preoperative chemotherapy was with 5‐fluorouracil and platinum‐based regimens according to local protocols.

All procedures were either performed or supervised by two experienced hepatobiliary surgeons. The choice of AR *versus* NAR was determined by the operating surgeon using a combination of preoperative and intraoperative evaluation. Patients with limited extrahepatic, intra‐abdominal disease (such as porta‐hepatis lymph node involvement or isolated upper‐quadrant peritoneal disease) were not excluded from resection. Liver transection was performed using the Cavitron Ultrasonic Aspirator® (CUSA) dissection device (Integra Life Sciences, Plainsboro, New Jersey, USA) under low central venous pressure with intermittent inflow occlusion.

R1 resection was defined as a microscopically positive margin. Perioperative morbidity was recorded. The highest grade complication was recorded for each patient using the Clavien--Dindo classification[19](#bjs550154-bib-0019){ref-type="ref"}. Major complications were those requiring surgical, endoscopic or radiological intervention (grade III) and ICU management (grade IV). Perioperative mortality referred to death during the same admission (in‐hospital) or within 90 days of surgery. Liver‐related complications were documented according to International Study Group of Liver Surgery definitions[20](#bjs550154-bib-0020){ref-type="ref"}, [21](#bjs550154-bib-0021){ref-type="ref"}.

Patient follow‐up {#bjs550154-sec-0008}
-----------------

After initial postoperative review at 1 month, all patients were followed up at 6‐month intervals, and annually indefinitely after 5 years. At each visit serum was obtained for liver function tests and estimation of tumour markers. In addition, CT of the abdomen and thorax was performed annually. Triple‐phase contrast‐enhanced MRI and PET were performed to define lesions considered suspicious on CT or with rising serum tumour markers.

Statistical analysis {#bjs550154-sec-0009}
--------------------

OS was defined as the time from hepatic resection to date of death (all‐cause mortality). DFS was defined as the time from liver surgery to date of either death or first evidence of recurrence (intrahepatic or extrahepatic). Patients who died during surgery were excluded from survival analyses.

Demographic descriptive statistics were reported using mean(s.d.) and median (i.q.r.) values depending on the distribution. Categorical variables were compared with the χ^2^ test. Continuous variables were compared using a two‐sided Student\'s *t* test or Mann--Whitney *U* test as appropriate. Kaplan--Meier curves were constructed for OS and DFS, and univariable survival analysis was performed using the log rank test.

To account for missing data, multiple imputation was used[22](#bjs550154-bib-0022){ref-type="ref"}. Twenty imputed data sets were created using the chained equations method. All prediction equations included age at operation, sex, temporal relationship, size of largest tumour, number of tumours, liver resection complications, resection margin, the censor variable for OS, the censor variable for DFS, the log of OS and the log of DFS time. Given the number of missing observations for tumour differentiation and serum carcinoembryonic antigen levels, these were not included in subsequent analyses. To assess the validity of the imputed data, the distributions of imputed, completed and observed data were compared. In addition, trace plots of means and standard deviations of the imputed values were generated to assess convergence of the 20 imputed chain equations.

To control for confounding imbalances in baseline co‐variables between the AR and NAR groups, an IPTW method of PS analysis was used[23](#bjs550154-bib-0023){ref-type="ref"}, [24](#bjs550154-bib-0024){ref-type="ref"}. Co‐variables included in the PS model were age, sex, year of liver operation, synchronicity, whether the patient received preoperative chemotherapy, number of tumours, maximum tumour size and use of the Pringle manoeuvre. The PS for each patient was then averaged across the imputed data sets[25](#bjs550154-bib-0025){ref-type="ref"} before being used to calculate a stabilized IPTW. IPTW‐adjusted Kaplan--Meier curves were then created[26](#bjs550154-bib-0026){ref-type="ref"}, and difference in survival was tested using a Cox proportional hazards (CPH) model. 'Doubly robust' multivariable CPH models[27](#bjs550154-bib-0027){ref-type="ref"} were then built by applying the IPTW and adjusting for potentially significant co‐variables identified in the univariable analysis (*P* \< 0·250), including tumour size, number and margin status. The purposeful selection of co‐variables method was used to select variables for the final model, which were then assessed for the validity of the proportional hazards assumption using Shoenfeld residuals and goodness‐of‐fit using Cox--Snell residuals. For sensitivity analyses, a complete case analysis was performed using the same CPH model.

A subgroup analysis was performed according to the size of the largest CRLM (less than 30 mm *versus* 30 mm or more); the above univariable and multivariable analysis was applied separately to each of these subgroups. A threshold of 30 mm was selected based on previous literature[2](#bjs550154-bib-0002){ref-type="ref"}. For the subgroup PS, the co‐variables used in the treatment model were the same as those for the whole cohort, with the exception of tumour size and use of the Pringle manoeuvre.

Data management and statistical analyses were performed using Stata® SE for Windows® version 15.1 (StataCorp, College Station, Texas, USA). The statistical significance level was set at α = 0·05.

Results {#bjs550154-sec-0010}
=======

A total of 391 patients underwent liver resection during the study period. Of these, 33 were excluded because they underwent simultaneous AR and NAR (25 patients), had a squamous cell primary tumour (4) or an R2 liver resection margin (4). The remaining 358 eligible patients were included in the study; 194 (54·2 per cent) underwent AR and 164 (45·8 per cent) had NAR.

Baseline characteristics are summarized in *Table* [1](#bjs550154-tbl-0001){ref-type="table"}. All resected lesions were metastatic adenocarcinomas. Median follow‐up was 34 (i.q.r. 16--68) months. There was a significant increase in the proportion of NAR performed over time (*P* = 0·005) (*Fig*. [1](#bjs550154-fig-0001){ref-type="fig"}). Some 48·8 per cent of resections in the NAR group were for solitary lesions. The proportions of types of AR are shown in *Table* [S1](#bjs550154-supitem-0001){ref-type="supplementary-material"} (supporting information). Some 139 of the 194 ARs (71·6 per cent) were of intermediate complexity, with a median complexity score of 4·87 (i.q.r. 4·39--6·21). There was no significant change in complexity score over time. The overall perioperative morbidity rate was 39·1 per cent (140 of 358), with a 9·1 per cent (57 of 353) major complication rate. There were five postoperative deaths (1·4 per cent) during the study period, all in the AR group. These deaths occurred during 2005--2007, and there were no further events in the following 9 years.

###### 

Characteristics of patients in anatomical and non‐anatomical groups

                                                                                    Non‐anatomical (*n* = 164)   Anatomical (*n* = 194)     *P* [†](#bjs550154-note-0004){ref-type="fn"}
  -------------------------------------------------------------------------------- ---------------------------- ------------------------ --------------------------------------------------
  Age (years)[\*](#bjs550154-note-0003){ref-type="fn"}                                     64 (57--71)                66 (57--73)          0·437[‡](#bjs550154-note-0005){ref-type="fn"}
  Sex ratio (M : F)                                                                          102 : 62                   123 : 71                               0·814
  Site of primary tumour                                                                                                                                       0·298
  Colon                                                                                     115 (70·1)                 126 (64·9)        
  Rectum                                                                                    49 (29·9)                  68 (35·1)         
  Temporal relationship                                                                                                                                        0·577
  Synchronous                                                                               86 (52·4)                  96 (49·5)         
  Metachronous                                                                              78 (47·6)                  98 (50·5)         
  Dukes\' class                                                                                                                                                0·443
  A/B                                                                                       55 (33·5)                  59 (30·4)         
  C                                                                                         96 (58·5)                  123 (63·4)        
  Missing                                                                                    13 (7·9)                   12 (6·2)         
  Primary surgery complication (*n* = 336)                                               17 of 154 (11·0)           18 of 182 (9·9)                            0·731
  Preoperative chemotherapy                                                             117 of 163 (71·8)              142 (73·2)                              0·765
  Perioperative RFA                                                                          5 (3·0)                    11 (5·7)                               0·241
  Year of liver surgery                                                                                                                                        0·006
  1999--2004                                                                                19 (11·6)                  40 (20·6)         
  2005--2010                                                                                77 (47·0)                  101 (52·1)        
  2011--2016                                                                                68 (41·5)                  53 (27·3)         
  Pringle manoeuvre (*n* = 324)                                                         136 of 150 (90·7)          140 of 174 (80·5)                           0·010
  Tumour size (cm)[\*](#bjs550154-note-0003){ref-type="fn"}                               2·5 (1·8--3·5)              4 (2·2--6·0)        \< 0·001[§](#bjs550154-note-1005){ref-type="fn"}
  No. of tumours                                                                                                                                               0·724
  Solitary                                                                                  80 (48·8)                  91 (46·9)         
  Multiple                                                                                  84 (51·2)                  103 (53·1)        
  2--3                                                                                      53 (32·3)                  72 (37·1)         
  \> 3                                                                                      31 (18·9)                  31 (16·0)         
  Duration of surgery (min)[\*](#bjs550154-note-0003){ref-type="fn"} (*n* = 325)          150 (100--180)             210 (150--270)       \< 0·001[§](#bjs550154-note-1005){ref-type="fn"}
  Estimated blood loss (ml)[\*](#bjs550154-note-0003){ref-type="fn"} (*n* = 344)          100 (50--200)              300 (120--500)       \< 0·001[§](#bjs550154-note-1005){ref-type="fn"}
  Blood transfusion (*n* = 354)                                                           1 of 163 (0·6)            21 of 191 (11·0)                          \< 0·001
  Hospital stay (days)[\*](#bjs550154-note-0003){ref-type="fn"} (*n* = 355)                  7 (6‐9)                   8 (7--11)           0·003[§](#bjs550154-note-1005){ref-type="fn"}
  Complications                                                                                                                                                0·006
  None or minor                                                                             147 (89·6)             149 of 189 (78·8)     
  Major (excluding death)                                                                   17 (10·4)                  40 (20·6)         
  Postoperative bleed                                                                         0 (0)                     2 (1·0)                                0·190
  Bile leak                                                                                  4 (2·4)                    13 (6·7)                               0·059
  Postoperative liver failure                                                                 0 (0)                     5 (2·6)                                0·038
  Perioperative mortality                                                                     0 (0)                     5 (2·6)                                0·038
  Resection margin                                                                                                                                             0·059
  R0                                                                                        144 (87·8)                 156 (80·4)        
  R1                                                                                        20 (12·2)                  38 (19·6)         
  Recurrence pattern                                                                         *n* = 90                  *n* = 132                               0·246
  Intrahepatic only                                                                          37 (41)                   41 (31·1)         
  Extrahepatic only                                                                          22 (24)                   43 (32·6)         
  Mixed intrahepatic and extrahepatic                                                        31 (34)                   48 (36·4)         
  Length of follow‐up (months)[\*](#bjs550154-note-0003){ref-type="fn"}                    35 (16--68)                32 (15--68)           0·51[§](#bjs550154-note-1005){ref-type="fn"}

Values in parentheses are percentages unless indicated otherwise;

values are median (i.q.r.). RFA, radiofrequency ablation.

χ^2^ test, except

Student\'s *t* test and

Mann--Whitney *U* test.

![Changes in hepatic resection type over time. AR, anatomical resection; NAR, non‐anatomical resection. *P* = 0·006 (χ^2^ test)](BJS5-3-521-g001){#bjs550154-fig-0001}

Multiple imputation and balancing of co‐variables using IPTW {#bjs550154-sec-0011}
------------------------------------------------------------

Data were not available for all patients; 6·1 per cent of data were missing for complications following resection of the primary colorectal tumour, 6·9 per cent for Dukes\' class, 0·3 per cent for preoperative chemotherapy, 3·9 per cent for blood loss, 1·1 per cent for blood transfusion, 9·5 per cent for Pringle manoeuvre, 9·2 per cent for duration of surgery, and 0·8 per cent for length of hospital stay. These variables were imputed for subsequent analysis using the method described above.

After application of a stabilized IPTW to the data set, the co‐variables of interest were all well balanced with a standard difference of less than 0·1 (*Table* [S2](#bjs550154-supitem-0001){ref-type="supplementary-material"}, supporting information)[28](#bjs550154-bib-0028){ref-type="ref"}. The mean(s.d.) stabilized IPTW was 0·989(0·410), indicating that the positivity assumption for IPTW had been maintained. For largest tumour less than 30 mm and largest tumour 30 mm or more subgroups, mean stabilized IPTW values were 1·003(0·250) and 1·003 (0·289) respectively.

Correlation between type of resection, clinicopathological characteristics and surgical outcomes {#bjs550154-sec-0012}
------------------------------------------------------------------------------------------------

Clinicopathological characteristics and surgical outcomes were compared by resection type (*Table* [1](#bjs550154-tbl-0001){ref-type="table"}). There were no differences between the two groups except for more frequent use of the Pringle manoeuvre during NAR (*P* = 0·010) and larger tumours in the AR group (*P* \< 0·001). There was also a significant association between resection type and year of liver surgery (*P* = 0·005), with a shift to predominantly NAR in later years (*Fig*. [1](#bjs550154-fig-0001){ref-type="fig"}).

The two groups did not differ significantly in margin status, postoperative bleeding or bile leak rates, but did differ significantly on all other reported outcomes, favouring NAR. The overall morbidity rate was lower in the NAR group than in the AR group (31·1 *versus* 44·4 per cent respectively; *P* = 0·037). There were fewer major complications in the NAR group (10·4 *versus* 20·6 per cent; *P* = 0·006). Five patients (all in the AR group) experienced postoperative liver failure during the study interval.

Overall and disease‐free survival {#bjs550154-sec-0013}
---------------------------------

After excluding five perioperative deaths, 353 patients were included in the OS and 350 in the DFS analysis (3 patients had missing recurrence data and so DFS could not be calculated). During the study period, median OS was 65 (95 per cent c.i. 49 to 92) months, and the 5‐year OS rate was 52·3 (95 per cent c.i. 46 to 58) per cent. The median DFS was 16 (12 to 20) months, and the 5‐year DFS rate was 28·1 (23 to 33) per cent.

The unadjusted univariable analysis for OS and DFS is presented in *Table* [2](#bjs550154-tbl-0002){ref-type="table"}. There was a significant difference in OS between AR and NAR groups (*P* = 0·004) (*Fig*. [2](#bjs550154-fig-0002){ref-type="fig"} *a*). Median OS was 48 months for AR and 141 months for NAR. Median DFS was longer for NAR than for AR (18 *versus* 15 months; *P* = 0·045) (*Fig*. [2](#bjs550154-fig-0002){ref-type="fig"} *b*).

###### 

Univariable analysis of overall and disease‐free survival

                                                                                     Overall survival    Disease‐free survival                     
  ------------------------------------------------------------------ --------------- ------------------ ----------------------- ------- ----- ---- ----------
  Age (years)                                                        \< 55           76                           101            0·155  75     18    0·941
  ≥ 55 and \< 65                                                     103             80                                           101   18         
  ≥ 65 and \< 75                                                     108             53                                           108   14         
  ≥ 75                                                               66              40                                           66    13         
  Sex                                                                F               129                          106            0·059  126    22    0·049
  M                                                                  224             58                                           224   15         
  Site of primary tumour                                             Colon           237                          65             0·483  234    16    0·618
  Rectum                                                             115             74                                           115   16         
  Temporal relationship                                              Synchronous     180                          48             0·073  177    11    0·004
  Metachronous                                                       173             95                                           173   23         
  Dukes\' class                                                      A/B             112                          68             0·291  111    23    0·205
  C                                                                  216             60                                           215   15         
  Primary surgery complication                                       No              297                          68             0·082  296    18    0·088
  Yes                                                                234             48                                           34    11         
  Preoperative chemotherapy                                          No              97                           68             0·624  96     23    0·111
  Yes                                                                255             65                                           253   13         
  Resection type                                                     Anatomical      189                          48             0·004  187    15    0·045
  Non‐anatomical                                                     164             141                                          163   18         
  Pringle manoeuvre                                                  No              47                           106            0·932  46     21    0·336
  Yes                                                                272             65                                           270   16         
  Tumour size (cm)                                                   \< 2·5          131                          74             0·008  131    18    0·145
  ≥ 2·5 and \< 5·0                                                   123             80                                           122   17         
  ≥ 5·0 and \< 10·0                                                  83              39                                           81    10         
  ≥ 10·0                                                             16              36                                           16    14         
  No. of tumours                                                     Solitary        170                          82             0·019  170    24   \< 0·001
  Multiple                                                           183             49                                           180   11         
  Duration of surgery (h)[\*](#bjs550154-note-0006){ref-type="fn"}   ≤ 2             93                         \(37\)           0·013  93     19    0·157
  \> 2 and ≤ 3                                                       99              101 (30)                                     98    15         
  \> 3 and ≤ 4                                                       79              53 (26)                                      77    13         
  \> 4                                                               50              46 (18)                                      50    13         
  Estimated blood loss (ml)                                          \< 100          89                           101            0·078  89     18    0·126
  ≥ 100 and \< 200                                                   88              106                                          87    23         
  ≥ 200 and \< 400                                                   81              60                                           80    15         
  ≥ 400                                                              81              46                                           80    10         
  Blood transfusion                                                  No              328                          72             0·004  325    16    0·285
  Yes                                                                21              31                                           21    16         
  Hospital stay (days)                                               ≤ 7             176                          92             0·014  173    21    0·030
  \> 7 and ≤ 14                                                      146             52                                           146   13         
  \> 14                                                              28              46                                           28    9          
  Complications                                                      None or minor   296                          79             0·007  293    18    0·056
  Major                                                              57              38                                           57    11         
  Resection margin                                                   R0              295                          80             0·011  293    18    0·027
  R1                                                                 58              43                                           57    11         

Values in parentheses represent the 25 per cent quantile as the median was not reached during the study period for all groups.

Log rank test.

![Survival curves for overall and disease‐free survival stratified by resection type. **a--d** Kaplan--Meier survival curves for overall survival (OS) and disease‐free survival (DFS) stratified by resection type in **a,b** unweighted and **c,d** inverse probability of treatment weighting (IPTW) data sets. The dotted line indicates the median value. **e,f** Survival curves for the final doubly robust Cox proportional hazards (CPH) model. AR, anatomical resection; NAR, non‐anatomical resection. **a** *P* = 0·004, **b** *P* = 0·045, **c** *P* = 0·221, **d** *P* = 0·273, **e** *P* = 0·537, **f** *P* = 0·429 (log rank test)](BJS5-3-521-g002){#bjs550154-fig-0002}

Multivariable analysis {#bjs550154-sec-0014}
----------------------

IPTW‐adjusted Kaplan--Meier curves for OS and DFS are shown in *Fig*. [2](#bjs550154-fig-0002){ref-type="fig"} *c,d*. Median OS was 52 and 91 months, and median DFS was 14 and 16 months, for AR and NAR groups respectively. There was no longer a significant difference between AR and NAR for either curve (*P* = 0·221 and *P* = 0·273 respectively). The final doubly robust IPTW CPH models for OS and DFS are shown in *Table* [3](#bjs550154-tbl-0003){ref-type="table"}. In this model, margin status was maintained based on previous research, indicating this to be a significant prognostic factor[29](#bjs550154-bib-0029){ref-type="ref"}, [30](#bjs550154-bib-0030){ref-type="ref"}.

###### 

Final doubly robust multivariable model for overall and disease‐free survival

                                        Hazard ratio      s.e.    *P*
  ---------------------------------- ------------------- ------ -------
  Overall survival                                              
  Resection type                                                 0·537
  Non‐anatomical                      1·00 (reference)          
  Anatomical                          1·21 (0·62, 1·28)   0·17  
  Tumour size (cm)                                               0·035
  \< 2·5                              1·00 (reference)          
  ≥ 2·5 and \< 5·0                    1·09 (0·75, 1·59)   0·21  
  ≥ 5·0 and \< 10·0                   1·81 (1·13, 2·90)   0·44  
  ≥ 10                                2·17 (1·08, 4·34)   0·77  
  No. of tumours                                                 0·035
  Solitary                            1·00 (reference)          
  Multiple                            1·48 (1·03, 2·12)   0·27  
  Resection margin                                               0·102
  R0                                  1·00 (reference)          
  R1                                  1·42 (0·93, 2·16)   0·30  
  Disease‐free survival                                         
  Resection type                                                 0·429
  Non‐anatomical                      1·00 (reference)          
  Anatomical                          1·12 (0·67, 1·18)   0·13  
  Temporal relationship                                          0·045
  Metachronous                        1·00 (reference)          
  Synchronous                         1·33 (1·01, 1·77)   0·19  
  Primary surgery complication                                   0·045
  No                                  1·00 (reference)          
  Yes                                 1·51 (1·01, 2·26)   0·31  
  Complications at liver resection                               0·026
  None or minor                       1·00 (reference)          
  Major                               1·49 (1·05, 2·11)   0·26  
  No. of tumours                                                 0·004
  Solitary                            1·00 (reference)          
  Multiple                            1·51 (1·14, 2·00)   0·22  
  Resection margin                                               0·092
  R0                                  1·00 (reference)          
  R1                                  1·34 (0·95, 1·90)   0·24  

Values in parentheses are 95 per cent confidence intervals.

Large or multiple metastases were associated with poor OS. Synchronous or multiple liver metastases, as well as complications after resection of the primary colorectal tumour or major complications at the time of CRLM resection, persisted as significant factors associated with poor DFS. Importantly, after adjusting for confounders, neither resection type (anatomical or non‐anatomical) or margin status significantly predicted OS or DFS. *Fig*. [2](#bjs550154-fig-0002){ref-type="fig"} *e,f* shows the survival curves for the averaged estimates across each of the imputed data sets derived from the doubly robust IPTW CPH model.

Recurrence pattern and salvage resection {#bjs550154-sec-0015}
----------------------------------------

Overall, 157 patients (43·9 per cent) developed intrahepatic recurrence, but there was no association between resection type and pattern of recurrence (intrahepatic only, extrahepatic only, or mixed) (*P* = 0·246) (*Table* [1](#bjs550154-tbl-0001){ref-type="table"}). Of patients with intrahepatic recurrence only, 41 underwent salvage resection. This was more likely if they had NAR as initial resection rather than AR (OR 2·31, 95 per cent c.i. 1·05 to 5·11; *P* = 0·022). Although the number of patients was small, in those who did proceed to salvage liver resection there was no difference in median OS whether they had AR or NAR initially (53 *versus* 55 months respectively; *P* = 0·430) (*Fig*. [S1](#bjs550154-supitem-0001){ref-type="supplementary-material"}, supporting information).

Subgroup analysis based on size of largest tumour {#bjs550154-sec-0016}
-------------------------------------------------

There was a significant effect modification on OS (*P* = 0·011) and DFS (*P* = 0·016) for NAR based on subgrouping according to the size of the largest CRLM (*Table* [S3](#bjs550154-supitem-0001){ref-type="supplementary-material"}, supporting information). Some 36·5 per cent (69 of 189) in the AR group and 61·0 per cent (100 of 164) in the NAR group had CRLMs smaller than 30 mm. Significantly more NAR procedures involving tumours of 30 mm or larger were performed over time (*P* = 0·032), reflecting the trend shown in *Fig*.  [1](#bjs550154-fig-0001){ref-type="fig"}. There was no difference in margin status between AR and NAR in either subgroup.

Patients with CRLMs smaller than 30 mm resected by a non‐anatomical approach had significantly better median OS (150 months; *P* \< 0·001) and DFS (27 months; *P* = 0·016) than those with lesions smaller than 30 mm resected anatomically or with lesions of 30 mm or greater resected by either technique (*Fig*. [S2a](#bjs550154-supitem-0001){ref-type="supplementary-material"}, supporting information). Similar results were observed in the IPTW‐adjusted survival curves (*Fig*. [S2b](#bjs550154-supitem-0001){ref-type="supplementary-material"}, supporting information).

Multivariable analysis of the final doubly robust IPTW CPH subgroup models is shown in *Table* [4](#bjs550154-tbl-0004){ref-type="table"}. In the largest tumour smaller than 30 mm subgroup, prognostic factors for poor OS included having an AR and multiple tumours. For DFS, having multiple tumours was the only hazardous prognostic factor. In the largest tumour at least 30 mm subgroup, complications after primary colorectal surgery and major complications following liver resection were significant for poorer OS. R1 margin status did not significantly influence survival. Major complications after liver resection as well as multiple tumours were also significantly associated with poorer DFS. For intrahepatic recurrences in the smaller than 30 mm subgroup, 27 patients underwent salvage resection. After initial NAR they were more likely to undergo repeated resection (OR 3·17, 95 per cent c.i. 1·18 to 8·47; *P* = 0·031). In the 30 mm or larger subgroup, only 14 patients underwent salvage resection and no association was found with AR or NAR at initial operation. These patients had significantly more extrahepatic recurrence than those in the smaller than 30 mm group (OR 2·06, 1·18 to 3·61; *P* = 0·011).

###### 

Final doubly robust multivariable model for overall and disease‐free survival for largest tumour size subgroups

                                      Size of largest tumour \< 30 mm   Size of largest tumour ≥ 30 mm                                     
  ---------------------------------- --------------------------------- -------------------------------- ------- ------------------- ------ -------
  Overall survival                                                                                                                         
  Resection type                                                                                         0·028                              0·469
  Non‐anatomical                             1·00 (reference)                                                   1·00 (reference)           
  Anatomical                                 1·81 (0·33, 0·94)                       0·15                       0·85 (0·76, 1·81)    0·26  
  Primary surgery complication                                                                                                              0·009
  No                                                --                                                          1·00 (reference)           
  Yes                                               --                                                          2·02 (0·29, 0·84)    0·13  
  Complications at liver resection                                                                                                          0·006
  None or minor                                     --                                                          1·00 (reference)           
  Major                                             --                                                          1·92 (1·20, 3·08)    0·46  
  No. of tumours                                                                                         0·020                               *‐*
  Solitary                                   1·00 (reference)                                                   --                         
  Multiple                                   2·02 (1·12, 3·65)                       0·61                       --                         
  Resection margin                                                                                       0·968                              0·070
  R0                                         1·00 (reference)                                                   1·00 (reference)           
  R1                                         0·98 (0·42, 2·31)                       0·43                       1·53 (0·97, 2·42)    0·36  
  Disease‐free survival                                                                                                                    
  Resection type                                                                                         0·175                              0·856
  Non‐anatomical                             1·00 (reference)                                                   1·00 (reference)           
  Anatomical                                 1·32 (0·51, 1·13)                       0·15                       0·97 (0·71, 1·51)    0·20  
  Primary surgery complication                                                                                                              0·050
  No                                                --                                                          1·00 (reference)           
  Yes                                               --                                                          1·68 (0·35, 1·00)    0·16  
  Complications at liver resection                                                                                                          0·017
  None or minor                                     --                                                          1·00 (reference)           
  Major                                             --                                                          1·65 (1·09, 2·49)    0·35  
  No. of tumours                                                                                         0·004                              0·002
  Solitary                                   1·00 (reference)                                                   1·00 (reference)           
  Multiple                                   1·87 (1·22, 2·85)                       0·40                       1·74 (1·22, 2·49)    0·32  
  Resection margin                                                                                       0·100                              0·992
  R0                                         1·00 (reference)                                                   1·00 (reference)           
  R1                                         1·76 (0·90, 3·44)                       0·60                       1·00 (0·66, 1·52)    0·21  

Values in parentheses are 95 per cent confidence intervals.

Discussion {#bjs550154-sec-0017}
==========

This study demonstrates that NAR has at least equivalent oncological outcomes to AR while proving to be safer. NAR is associated with a higher rate of salvage resection in the event of intrahepatic recurrence. Surgical complications after either primary tumour or liver resection can impact on long‐term DFS and OS. In the authors\' opinion, if NAR is possible, it is the preferred approach for treating CRLM, particularly for lesions smaller than 30 mm.

The larger median size of tumours in the AR compared with the NAR group in the present study reflects the greater likelihood of these tumours abutting critical vascular or biliary structures, thereby necessitating a more extensive operation[31](#bjs550154-bib-0031){ref-type="ref"}. However, after adjusting for the effect of tumour size and number, the type of liver resection (AR or NAR) did not impact on either OS or DFS. There was a significant increase in the proportion of NARs undertaken over the 17‐year study interval, as well as an increase in the median size of the tumours resected non‐anatomically. This was despite no change in complexity score amongst ARs. This counters any suggestion that the NAR group is comprised only of technically easy 'chip out' resections. The PS IPTW analysis also controlled for any effect on outcome due to the proportional increase in NAR over time.

In subgroup analysis, AR was a poor prognostic factor for OS, but not for DFS, in patients with tumours smaller than 30 mm. This may be because patients who initially presented with small tumours were more likely to proceed to salvage resection for intrahepatic recurrence if the original resection was non‐anatomical rather than an AR, which would leave a smaller liver remnant. In the event of intrahepatic recurrence there was equivalent OS regardless of the initial approach to resection, although the number of events for analysis was small. In contrast for large (at least 30 mm) tumours, no association between salvage resection and initial resection type was observed, possibly because these patients were more likely to present with additional extrahepatic recurrence.

NAR was consistently safer than AR across all studied outcome measures including overall morbidity, mortality, blood loss, transfusion requirement and length of hospital stay. Importantly, there was no difference in bile leak rates between the two resection types. Major complications after liver resection or at the time of the primary colorectal resection influenced survival after liver resection for CRLM. This is consistent with findings from a study[32](#bjs550154-bib-0032){ref-type="ref"} using pooled individual patient data from three large phase III clinical trials of patients who had curative resection of a primary colorectal cancer. The relationship between surgical complications and oncological outcome is not fully understood, but is likely to involve numerous immune regulatory mechanisms and release of inflammatory and growth factors[33](#bjs550154-bib-0033){ref-type="ref"}, [34](#bjs550154-bib-0034){ref-type="ref"}.

The original hypothesis of the present study was not supported by the finding that a microscopically positive resection (R1) margin did not predict DFS or OS in any of the multivariable models. This remains a contentious and unresolved issue in the surgical literature. Although several large studies[29](#bjs550154-bib-0029){ref-type="ref"}, [35](#bjs550154-bib-0035){ref-type="ref"}, [36](#bjs550154-bib-0036){ref-type="ref"}, [37](#bjs550154-bib-0037){ref-type="ref"} have shown that an R1 resection does increase the risk of tumour recurrence, others[38](#bjs550154-bib-0038){ref-type="ref"}, [39](#bjs550154-bib-0039){ref-type="ref"} did not observe this. Regardless, the predominant paradigm is that evidence of residual disease at the resection margin increases the risk of tumour recurrence. Patients with large tumours had a higher rate of adjacent micrometastases compared with those with small tumours[40](#bjs550154-bib-0040){ref-type="ref"}, [41](#bjs550154-bib-0041){ref-type="ref"}. Tumour biology may eclipse the impact of relatively few residual tumour cells at the surgical margin[29](#bjs550154-bib-0029){ref-type="ref"}. In the present model, it is likely that margin status was outperformed by tumour size and number, possibly as a surrogate of tumour biology, in determining long‐term outcome. Multiple or large metastases were poor prognostic factors for OS, whereas multiple metastases or synchronous bowel and liver resection, as well as complications after primary resection and major complications after liver resection, were poor prognostic factors for DFS.

Limitations of this study include its retrospective design and lack of genetic data in the analysis. A recent study[42](#bjs550154-bib-0042){ref-type="ref"} showed that amongst *KRAS* mutant tumours, which are known to be associated with increased rates of vascular invasion, AR conferred a benefit to intrahepatic recurrence and overall DFS. Interestingly, even in the *KRAS* mutant subgroup, R1 status did not predict DFS. Although *KRAS* mutations are present in 30--40 per cent of colorectal tumours with liver metastases, there are many other potential mutational combinations in CRLMs. Future studies will need to consider stratifying patients according to mutation status, as well as other indicators of underlying tumour biology.
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